




## Farmacología humana, 7.<sup>a</sup> edición


| Capítulo del libro  | Título del video   | URL   |
|---|--|---|
| 02: Acciones de los fármacos I. Interacciones entre fármaco y receptor                      | Pharmacodynamics: Agonist, partial agonist and antagonist            | <a href="https://www.osmosis.org/learn/Pharmacodynamics:_Agonist,_partial_agonist_and_antagonist">https://www.osmosis.org/learn/Pharmacodynamics:_Agonist,_partial_agonist_and_antagonist</a>                       |
| 02: Acciones de los fármacos I. Interacciones entre fármaco y receptor                      | Pharmacodynamics: Desensitization and tolerance                      | <a href="https://osmosis.org/learn/Pharmacodynamics:_Desensitization_and_tolerance">https://osmosis.org/learn/Pharmacodynamics:_Desensitization_and_tolerance</a>   |
| 02: Acciones de los fármacos I. Interacciones entre fármaco y receptor                      | Pharmacodynamics: Drug-receptor interactions                         | <a href="https://osmosis.org/learn/Pharmacodynamics:_Drug-receptor_interactions">https://osmosis.org/learn/Pharmacodynamics:_Drug-receptor_interactions</a>   |
| 03: Acciones de los fármacos II. Dianas y mecanismos moleculares                            | Cell signaling pathways  | <a href="https://osmosis.org/learn/Cell_signaling_pathways">https://osmosis.org/learn/Cell_signaling_pathways</a>   |
| 03: Acciones de los fármacos II. Dianas y mecanismos moleculares                            | Enzyme function  | <a href="https://osmosis.org/learn/Enzyme_function">https://osmosis.org/learn/Enzyme_function</a>   |
| 03: Acciones de los fármacos II. Dianas y mecanismos moleculares                            | Selective permeability of the cell membrane                          | <a href="https://osmosis.org/learn/Selective_permeability_of_the_cell_membrane">https://osmosis.org/learn/Selective_permeability_of_the_cell_membrane</a>   |
| 04: Farmacocinética: absorción, distribución y eliminación de los fármacos                  | Pharmacokinetics: Drug absorption and distribution                   | <a href="https://osmosis.org/learn/Pharmacokinetics:_Drug_absorption_and_distribution">https://osmosis.org/learn/Pharmacokinetics:_Drug_absorption_and_distribution</a>   |
| 04: Farmacocinética: absorción, distribución y eliminación de los fármacos                  | Pharmacokinetics: Drug elimination and clearance                     | <a href="https://osmosis.org/learn/Pharmacokinetics:_Drug_elimination_and_clearance">https://osmosis.org/learn/Pharmacokinetics:_Drug_elimination_and_clearance</a>   |
| 05: Metabolismo de los fármacos   | Pharmacokinetics: Drug metabolism                                    | <a href="https://osmosis.org/learn/Pharmacokinetics:_Drug_metabolism">https://osmosis.org/learn/Pharmacokinetics:_Drug_metabolism</a>   |
| 06: Farmacocinética clínica, individualización del tratamiento y monitorización de fármacos | Drug administration and dosing regimens                              | <a href="https://osmosis.org/learn/Drug_administration_and_dosing_regimens">https://osmosis.org/learn/Drug_administration_and_dosing_regimens</a>   |
| 07: Reacciones adversas a los medicamentos. Farmacovigilancia                               | Approach to medication-induced movement disorders: Clinical sciences | <a href="https://www.osmosis.org/learn/Approach_to_medication-induced_movement_disorders:_Clinical_sciences">https://www.osmosis.org/learn/Approach_to_medication-induced_movement_disorders:_Clinical_sciences</a> |
| 07: Reacciones adversas a los medicamentos. Farmacovigilancia                               | Medication overdoses and toxicities: Pathology review                | <a href="https://www.osmosis.org/learn/Medication_overdoses_and_toxicities:_Pathology_review">https://www.osmosis.org/learn/Medication_overdoses_and_toxicities:_Pathology_review</a>                               |
| 07: Reacciones adversas a los medicamentos. Farmacovigilancia                               | Medication-induced constipation: Clinical sciences                   | <a href="https://www.osmosis.org/learn/Medication-induced_constipation:_Clinical_sciences">https://www.osmosis.org/learn/Medication-induced_constipation:_Clinical_sciences</a>                                     |



## Farmacología humana, 7.<sup>a</sup> edición



| Capítulo del libro  | Título del video   | URL   |
|---|--|---|
| 08: Variabilidad en la respuesta a los fármacos: factores genéticos, ambientales y fisiológicos     | Approach to prenatal teratogen exposure: Clinical sciences | <a href="https://www.osmosis.org/learn/Approach_to_prenatal_teratogen_exposure:_Clinical_sciences">https://www.osmosis.org/learn/Approach_to_prenatal_teratogen_exposure:_Clinical_sciences</a> |
| 08: Variabilidad en la respuesta a los fármacos: factores genéticos, ambientales y fisiológicos     | Approach to respiratory acidosis: Clinical sciences        | <a href="https://www.osmosis.org/learn/Approach_to_respiratory_acidosis:_Clinical_sciences">https://www.osmosis.org/learn/Approach_to_respiratory_acidosis:_Clinical_sciences</a>               |
| 09: Influencia de los factores patológicos sobre la respuesta a los fármacos y efectos iatrogénicos | Drug administration and dosing regimens                    | <a href="https://osmosis.org/learn/Drug_administration_and_dosing_regimens">https://osmosis.org/learn/Drug_administration_and_dosing_regimens</a>   |
| 10: Interacciones de fármacos y sus implicaciones clínicas  | Medication overdoses and toxicities: Pathology review      | <a href="https://www.osmosis.org/learn/Medication_overdoses_and_toxicities:_Pathology_review">https://www.osmosis.org/learn/Medication_overdoses_and_toxicities:_Pathology_review</a>           |
| 10: Interacciones de fármacos y sus implicaciones clínicas  | Pharmacokinetics: Drug metabolism                          | <a href="https://osmosis.org/learn/Pharmacokinetics:_Drug_metabolism">https://osmosis.org/learn/Pharmacokinetics:_Drug_metabolism</a>   |
| 12: Ensayos clínicos. Farmacoepidemiología. Farmacoeconomía   | Clinical trials  | <a href="https://www.osmosis.org/learn/Clinical_Trials">https://www.osmosis.org/learn/Clinical_Trials</a>   |
| 13: Farmacología general del sistema nervioso autónomo  | Introduction to the somatic and autonomic nervous systems  | <a href="https://www.osmosis.org/learn/Introduction_to_the_somatic_and_autonomic_nervous_systems">https://www.osmosis.org/learn/Introduction_to_the_somatic_and_autonomic_nervous_systems</a>   |
| 14: Transmisión colinérgica. Fármacos agonistas colinérgicos  | Cholinergic receptors                                      | <a href="https://osmosis.org/learn/Cholinergic_receptors">https://osmosis.org/learn/Cholinergic_receptors</a>   |
| 14: Transmisión colinérgica. Fármacos agonistas colinérgicos  | Cholinomimetics: Direct Agonists                           | <a href="https://www.osmosis.org/learn/Cholinomimetics:_Direct_agonists">https://www.osmosis.org/learn/Cholinomimetics:_Direct_agonists</a>   |
| 14: Transmisión colinérgica. Fármacos agonistas colinérgicos  | Cholinomimetics: Indirect agonists (anticholinesterases)   | <a href="https://www.osmosis.org/learn/Cholinomimetics:_Indirect_agonists_(anticholinesterases)">https://www.osmosis.org/learn/Cholinomimetics:_Indirect_agonists_(anticholinesterases)</a>     |



## Farmacología humana, 7.<sup>a</sup> edición




| Capítulo del libro  | Título del video                       | URL   |
|---|--|---|
| 15: Fármacos antagonistas colinérgicos muscarínicos                                     | Muscarinic antagonists                 | <a href="https://osmosis.org/learn/Muscarinic_antagonists">https://osmosis.org/learn/Muscarinic_antagonists</a>   |
| 16: Transmisión catecolaminérgica. Fármacos agonistas catecolaminérgicos                | Adrenergic receptors                   | <a href="https://osmosis.org/learn/Adrenergic_receptors">https://osmosis.org/learn/Adrenergic_receptors</a>   |
| 16: Transmisión catecolaminérgica. Fármacos agonistas catecolaminérgicos                | Sympatholytics: Alpha-2 agonists       | <a href="https://www.osmosis.org/learn/Sympatholytics:_Alpha-2_agonists">https://www.osmosis.org/learn/Sympatholytics:_Alpha-2_agonists</a>   |
| 16: Transmisión catecolaminérgica. Fármacos agonistas catecolaminérgicos                | Sympathomimetics: Direct agonists      | <a href="https://www.osmosis.org/learn/Sympathomimetics:_Direct_agonists">https://www.osmosis.org/learn/Sympathomimetics:_Direct_agonists</a>                                       |
| 17: Fármacos que modifican la actividad simpática                                       | Adrenergic antagonists: Alpha blockers | <a href="https://osmosis.org/learn/Peripheral_postsynaptic_anti-adrenergics:_Alpha_blockers">https://osmosis.org/learn/Peripheral_postsynaptic_anti-adrenergics:_Alpha_blockers</a> |
| 17: Fármacos que modifican la actividad simpática                                       | Adrenergic antagonists: Beta blockers  | <a href="https://osmosis.org/learn/Peripheral_postsynaptic_anti-adrenergics:_Beta_blockers">https://osmosis.org/learn/Peripheral_postsynaptic_anti-adrenergics:_Beta_blockers</a>   |
| 17: Fármacos que modifican la actividad simpática                                       | Adrenergic antagonists: Presynaptic    | <a href="https://osmosis.org/learn/Peripheral_presynaptic_anti-adrenergics">https://osmosis.org/learn/Peripheral_presynaptic_anti-adrenergics</a>                                   |
| 18: Fármacos bloqueantes de la placa motriz y bloqueantes ganglionares                  | Neuromuscular blockers                 | <a href="https://osmosis.org/learn/Neuromuscular_blockers">https://osmosis.org/learn/Neuromuscular_blockers</a>   |
| 18: Fármacos bloqueantes de la placa motriz y bloqueantes ganglionares                  | Neuromuscular junction and motor unit  | <a href="https://osmosis.org/learn/Neuromuscular_junction_and_motor_unit">https://osmosis.org/learn/Neuromuscular_junction_and_motor_unit</a>                                       |
| 19: Anestésicos locales   | Local anesthetics                      | <a href="https://osmosis.org/learn/Local_anesthetics">https://osmosis.org/learn/Local_anesthetics</a>   |
| 20: Mediadores celulares I. Histamina y 5-hidroxitriptamina. Farmacología de la migraña | Antihistamines for allergies           | <a href="https://osmosis.org/learn/Antihistamines_for_allergies">https://osmosis.org/learn/Antihistamines_for_allergies</a>   |
| 20: Mediadores celulares I. Histamina y 5-hidroxitriptamina. Farmacología de la migraña | Migraine medications                   | <a href="https://osmosis.org/learn/Migraine_medications">https://osmosis.org/learn/Migraine_medications</a>   |



## Farmacología humana, 7.<sup>a</sup> edición



| Capítulo del libro   | Título del video  | URL   |
|--|---|---|
| 21: Mediadores celulares II.<br>Eicosanoides, óxido nítrico y factor activador de plaquetas      | Inflammation  | <a href="https://osmosis.org/learn/Inflammation">https://osmosis.org/learn/Inflammation</a>   |
| 21: Mediadores celulares II.<br>Eicosanoides, óxido nítrico y factor activador de plaquetas      | Platelet plug formation (primary hemostasis)                    | <a href="https://osmosis.org/learn/Platelet_plug_formation_(primary_hemostasis)">https://osmosis.org/learn/Platelet_plug_formation_(primary_hemostasis)</a>   |
| 22: Mediadores celulares III.<br>Angiotensinas, cininas, citocinas y otros mediadores peptídicos | Cytokines   | <a href="https://osmosis.org/learn/Cytokines">https://osmosis.org/learn/Cytokines</a>   |
| 23: Fármacos analgésicos antipiréticos y antiinflamatorios no esteroideos. Antiartríticos        | Non-steroidal anti-inflammatory drugs                           | <a href="https://osmosis.org/learn/Non-steroidal_anti-inflammatory_drugs">https://osmosis.org/learn/Non-steroidal_anti-inflammatory_drugs</a>   |
| 23: Fármacos analgésicos antipiréticos y antiinflamatorios no esteroideos. Antiartríticos        | Acetaminophen   | <a href="https://osmosis.org/learn/Acetaminophen_(Paracetamol)">https://osmosis.org/learn/Acetaminophen_(Paracetamol)</a>   |
| 24: Farmacología de la respuesta inmunitaria   | Non-biologic disease modifying anti-rheumatic drugs (DMARDs)    | <a href="https://www.osmosis.org/learn/Non-biologic_disease_modifying_anti-rheumatic_drugs_(DMARDs)">https://www.osmosis.org/learn/Non-biologic_disease_modifying_anti-rheumatic_drugs_(DMARDs)</a>         |
| 24: Farmacología de la respuesta inmunitaria   | Non-corticosteroid immunosuppressants and immunotherapies       | <a href="https://www.osmosis.org/learn/Non-corticosteroid_immunosuppressants_and_immunotherapies">https://www.osmosis.org/learn/Non-corticosteroid_immunosuppressants_and_immunotherapies</a>               |
| 25: Neurotransmisión en el sistema nervioso central  | Monoamine oxidase inhibitors                                    | <a href="https://osmosis.org/learn/Monoamine_oxidase_inhibitors">https://osmosis.org/learn/Monoamine_oxidase_inhibitors</a>   |
| 26: Fármacos analgésicos opioides  | Opioid agonists, mixed agonist-antagonists and partial agonists | <a href="https://www.osmosis.org/learn/Opioid_agonists,_mixed_agonist-antagonists,_and_partial_agonists">https://www.osmosis.org/learn/Opioid_agonists,_mixed_agonist-antagonists,_and_partial_agonists</a> |
| 26: Fármacos analgésicos opioides  | Opioid antagonists  | <a href="https://osmosis.org/learn/Opioid_antagonists">https://osmosis.org/learn/Opioid_antagonists</a>   |
| 27: Fármacos ansiolíticos y sedantes. Farmacología de los trastornos del sueño                   | Anticonvulsants and anxiolytics: Barbiturates                   | <a href="https://osmosis.org/learn/Anticonvulsants_and_anxiolytics:_Barbiturates">https://osmosis.org/learn/Anticonvulsants_and_anxiolytics:_Barbiturates</a>   |
| 27: Fármacos ansiolíticos y sedantes. Farmacología de los trastornos del sueño                   | Anticonvulsants and anxiolytics: Benzodiazepines                | <a href="https://osmosis.org/learn/Anticonvulsants_and_anxiolytics:_Benzodiazepines">https://osmosis.org/learn/Anticonvulsants_and_anxiolytics:_Benzodiazepines</a>   |
| 27: Fármacos ansiolíticos y sedantes. Farmacología de los trastornos del sueño                   | Insomnia  | <a href="https://osmosis.org/learn/Insomnia">https://osmosis.org/learn/Insomnia</a>   |
| 28: Fármacos anestésicos generales   | General anesthetics   | <a href="https://osmosis.org/learn/General_anesthetics">https://osmosis.org/learn/General_anesthetics</a>   |



## Farmacología humana, 7.<sup>a</sup> edición


| Capítulo del libro   | Título del video   | URL   |
|--|--|---|
| 29: Fármacos antiepilépticos y anticonvulsivantes                      | Nonbenzodiazepine anticonvulsants                        | <a href="https://osmosis.org/learn/Nonbenzodiazepine_anticonvulsants">https://osmosis.org/learn/Nonbenzodiazepine_anticonvulsants</a>   |
| 30: Farmacología de los movimientos anormales. Fármacos antiespásticos | Muscarinic antagonists                                   | <a href="https://osmosis.org/learn/Muscarinic_antagonists">https://osmosis.org/learn/Muscarinic_antagonists</a>   |
| 30: Farmacología de los movimientos anormales. Fármacos antiespásticos | Anti-parkinson medications                               | <a href="https://osmosis.org/learn/Anti-parkinson_medications">https://osmosis.org/learn/Anti-parkinson_medications</a>   |
| 31: Fármacos antipsicóticos  | Atypical antipsychotics                                  | <a href="https://osmosis.org/learn/Atypical_antipsychotics">https://osmosis.org/learn/Atypical_antipsychotics</a>   |
| 31: Fármacos antipsicóticos  | Typical antipsychotics                                   | <a href="https://osmosis.org/learn/Typical_antipsychotics">https://osmosis.org/learn/Typical_antipsychotics</a>   |
| 32: Farmacología de la depresión y el trastorno bipolar                | Atypical antidepressants                                 | <a href="https://osmosis.org/learn/Atypical_antidepressants">https://osmosis.org/learn/Atypical_antidepressants</a>   |
| 32: Farmacología de la depresión y el trastorno bipolar                | Selective serotonin reuptake inhibitors                  | <a href="https://osmosis.org/learn/Selective_serotonin_reuptake_inhibitors">https://osmosis.org/learn/Selective_serotonin_reuptake_inhibitors</a>   |
| 32: Farmacología de la depresión y el trastorno bipolar                | Serotonin and norepinephrine reuptake inhibitors         | <a href="https://osmosis.org/learn/Serotonin_and_norepinephrine_reuptake_inhibitors">https://osmosis.org/learn/Serotonin_and_norepinephrine_reuptake_inhibitors</a>                         |
| 32: Farmacología de la depresión y el trastorno bipolar                | Tricyclic antidepressants                                | <a href="https://osmosis.org/learn/Tricyclic_antidepressants">https://osmosis.org/learn/Tricyclic_antidepressants</a>   |
| 32: Farmacología de la depresión y el trastorno bipolar                | Atypical antipsychotics                                  | <a href="https://osmosis.org/learn/Atypical_antipsychotics">https://osmosis.org/learn/Atypical_antipsychotics</a>   |
| 32: Farmacología de la depresión y el trastorno bipolar                | Lithium  | <a href="https://osmosis.org/learn/Lithium_(Medication)">https://osmosis.org/learn/Lithium_(Medication)</a>   |
| 33: Trastornos adictivos. Farmacodependencias                          | Cannabis dependence                                      | <a href="https://osmosis.org/learn/Cannabis_dependence">https://osmosis.org/learn/Cannabis_dependence</a>   |
| 33: Trastornos adictivos. Farmacodependencias                          | Cocaine dependence                                       | <a href="https://osmosis.org/learn/Cocaine_dependence">https://osmosis.org/learn/Cocaine_dependence</a>   |
| 33: Trastornos adictivos. Farmacodependencias                          | Opioid dependence  | <a href="https://osmosis.org/learn/Opioid_dependence">https://osmosis.org/learn/Opioid_dependence</a>   |
| 33: Trastornos adictivos. Farmacodependencias                          | Substance use disorder: Clinical sciences                | <a href="https://www.osmosis.org/learn/Substance_use_disorder:_Clinical_sciences">https://www.osmosis.org/learn/Substance_use_disorder:_Clinical_sciences</a>                               |
| 33: Trastornos adictivos. Farmacodependencias                          | Tobacco dependence                                       | <a href="https://osmosis.org/learn/Tobacco_dependence">https://osmosis.org/learn/Tobacco_dependence</a>   |
| 34: Farmacología de las demencias y las conductas anormales            | Cholinomimetics: Indirect agonists (anticholinesterases) | <a href="https://www.osmosis.org/learn/Cholinomimetics:_Indirect_agonists_(anticholinesterases)">https://www.osmosis.org/learn/Cholinomimetics:_Indirect_agonists_(anticholinesterases)</a> |
| 34: Farmacología de las demencias y las conductas anormales            | Medications for neurodegenerative diseases               | <a href="https://www.osmosis.org/learn/Medications_for_neurodegenerative_diseases">https://www.osmosis.org/learn/Medications_for_neurodegenerative_diseases</a>                             |



## Farmacología humana, 7.<sup>a</sup> edición



| Capítulo del libro  | Título del video  | URL   |
|---|---|---|
| 35: Farmacología de la insuficiencia cardíaca I. Glucósidos digitálicos y otros inotrópicos                         | Heart failure   | <a href="https://www.osmosis.org/learn/Heart_failure">https://www.osmosis.org/learn/Heart_failure</a>   |
| 35: Farmacología de la insuficiencia cardíaca I. Glucósidos digitálicos y otros inotrópicos                         | Positive inotropic medications                                | <a href="https://osmosis.org/learn/Positive_inotropic_medications">https://osmosis.org/learn/Positive_inotropic_medications</a>   |
| 36: Farmacología de la insuficiencia cardíaca II. Fármacos diuréticos, vasodilatadores e inhibidores neurohumorales | Adrenergic antagonists: Beta blockers                         | <a href="https://osmosis.org/learn/Peripheral_postsynaptic_antidrenergics:_Beta_blockers">https://osmosis.org/learn/Peripheral_postsynaptic_antidrenergics:_Beta_blockers</a>                 |
| 36: Farmacología de la insuficiencia cardíaca II. Fármacos diuréticos, vasodilatadores e inhibidores neurohumorales | ACE inhibitors, ARBs and direct renin inhibitors              | <a href="https://osmosis.org/learn/ACE_inhibitors_and_ARBs">https://osmosis.org/learn/ACE_inhibitors_and_ARBs</a>   |
| 36: Farmacología de la insuficiencia cardíaca II. Fármacos diuréticos, vasodilatadores e inhibidores neurohumorales | Mineralocorticoids and mineralocorticoid antagonists          | <a href="https://osmosis.org/learn/Mineralocorticoids_and_mineralocorticoid_antagonists">https://osmosis.org/learn/Mineralocorticoids_and_mineralocorticoid_antagonists</a>                   |
| 37: Fármacos antiarrítmicos   | Class I antiarrhythmics: Sodium channel blockers              | <a href="https://osmosis.org/learn/Class_I_Antiarrhythmics:_Sodium_channel_blockers">https://osmosis.org/learn/Class_I_Antiarrhythmics:_Sodium_channel_blockers</a>                           |
| 37: Fármacos antiarrítmicos   | Class II antiarrhythmics: Beta blockers                       | <a href="https://osmosis.org/learn/Class_II_Antiarrhythmics:_Beta_blockers">https://osmosis.org/learn/Class_II_Antiarrhythmics:_Beta_blockers</a>   |
| 37: Fármacos antiarrítmicos   | Class III antiarrhythmics: Potassium channel blockers         | <a href="https://osmosis.org/learn/Class_III_Antiarrhythmics:_Potassium_channel_blockers">https://osmosis.org/learn/Class_III_Antiarrhythmics:_Potassium_channel_blockers</a>                 |
| 37: Fármacos antiarrítmicos   | Class IV antiarrhythmics: Calcium channel blockers and others | <a href="https://osmosis.org/learn/Class_IV_Antiarrhythmics:_Calcium_channel_blockers_and_others">https://osmosis.org/learn/Class_IV_Antiarrhythmics:_Calcium_channel_blockers_and_others</a> |
| 38: Farmacología de la hipertensión arterial y la insuficiencia vascular periférica                                 | Sympatholytics: Alpha-2 agonists                              | <a href="https://www.osmosis.org/learn/Sympatholytics:_Alpha-2_agonists">https://www.osmosis.org/learn/Sympatholytics:_Alpha-2_agonists</a>   |
| 38: Farmacología de la hipertensión arterial y la insuficiencia vascular periférica                                 | Adrenergic antagonists: Alpha blockers                        | <a href="https://osmosis.org/learn/Peripheral_postsynaptic_antidrenergics:_Alpha_blockers">https://osmosis.org/learn/Peripheral_postsynaptic_antidrenergics:_Alpha_blockers</a>               |
| 38: Farmacología de la hipertensión arterial y la insuficiencia vascular periférica                                 | Adrenergic antagonists: Beta blockers                         | <a href="https://osmosis.org/learn/Peripheral_postsynaptic_antidrenergics:_Beta_blockers">https://osmosis.org/learn/Peripheral_postsynaptic_antidrenergics:_Beta_blockers</a>                 |
| 38: Farmacología de la hipertensión arterial y la insuficiencia vascular periférica                                 | Loop diuretics  | <a href="https://osmosis.org/learn/Loop_diuretics">https://osmosis.org/learn/Loop_diuretics</a>   |
| 38: Farmacología de la hipertensión arterial y la insuficiencia vascular periférica                                 | ACE inhibitors, ARBs and direct renin inhibitors              | <a href="https://osmosis.org/learn/ACE_inhibitors_and_ARBs">https://osmosis.org/learn/ACE_inhibitors_and_ARBs</a>   |
| 38: Farmacología de la hipertensión arterial y la insuficiencia vascular periférica                                 | cGMP mediated smooth muscle vasodilators                      | <a href="https://osmosis.org/learn/Vasodilators:_cGMP_mediated_smooth_muscle_vasodilators">https://osmosis.org/learn/Vasodilators:_cGMP_mediated_smooth_muscle_vasodilators</a>               |



## Farmacología humana, 7.ª edición




| Capítulo del libro  | Título del video  | URL   |
|---|---|---|
| 38: Farmacología de la hipertensión arterial y la insuficiencia vascular periférica                               | Calcium channel blockers  | <a href="https://www.osmosis.org/learn/Calcium_channel_blockers">https://www.osmosis.org/learn/Calcium_channel_blockers</a>   |
| 38: Farmacología de la hipertensión arterial y la insuficiencia vascular periférica                               | Potassium sparing diuretics                                     | <a href="https://osmosis.org/learn/Potassium_sparing_diuretics">https://osmosis.org/learn/Potassium_sparing_diuretics</a>   |
| 38: Farmacología de la hipertensión arterial y la insuficiencia vascular periférica                               | Thiazide and thiazide-like diuretics                            | <a href="https://osmosis.org/learn/Thiazide_and_thiazide-like_diuretics">https://osmosis.org/learn/Thiazide_and_thiazide-like_diuretics</a>   |
| 39: Fármacos antianginosos  | Adrenergic antagonists: Beta blockers                           | <a href="https://osmosis.org/learn/Peripheral_postsynaptic_antidrenergics:_Beta_blockers">https://osmosis.org/learn/Peripheral_postsynaptic_antidrenergics:_Beta_blockers</a>                               |
| 39: Fármacos antianginosos  | cGMP mediated smooth muscle vasodilators                        | <a href="https://osmosis.org/learn/Vasodilators:_cGMP_mediated_smooth_muscle_vasodilators">https://osmosis.org/learn/Vasodilators:_cGMP_mediated_smooth_muscle_vasodilators</a>                             |
| 39: Fármacos antianginosos  | Calcium channel blockers  | <a href="https://www.osmosis.org/learn/Calcium_channel_blockers">https://www.osmosis.org/learn/Calcium_channel_blockers</a>   |
| 40: Fármacos antiasmáticos y broncodilatadores  | Bronchodilators: Beta 2-agonists and muscarinic antagonists     | <a href="https://osmosis.org/learn/Bronchodilators:_Beta_2-agonists_and_muscarinic_antagonists">https://osmosis.org/learn/Bronchodilators:_Beta_2-agonists_and_muscarinic_antagonists</a>                   |
| 40: Fármacos antiasmáticos y broncodilatadores  | Bronchodilators: Leukotriene antagonists and methylxanthines    | <a href="https://osmosis.org/learn/Bronchodilators:_Leukotriene_antagonists_and_methylxanthines">https://osmosis.org/learn/Bronchodilators:_Leukotriene_antagonists_and_methylxanthines</a>                 |
| 40: Fármacos antiasmáticos y broncodilatadores  | Pulmonary corticosteroids and mast cell inhibitors              | <a href="https://www.osmosis.org/learn/Pulmonary_corticosteroids_and_mast_cell_inhibitors">https://www.osmosis.org/learn/Pulmonary_corticosteroids_and_mast_cell_inhibitors</a>                             |
| 41: Fármacos antitusígenos y mucoactivos. Distrés respiratorio. Fibrosis quística. Estimulantes de la respiración | Opioid agonists, mixed agonist-antagonists and partial agonists | <a href="https://www.osmosis.org/learn/Opioid_agonists,_mixed_agonist-antagonists,_and_partial_agonists">https://www.osmosis.org/learn/Opioid_agonists,_mixed_agonist-antagonists,_and_partial_agonists</a> |
| 41: Fármacos antitusígenos y mucoactivos. Distrés respiratorio. Fibrosis quística. Estimulantes de la respiración | Cystic fibrosis   | <a href="https://osmosis.org/learn/Cystic_fibrosis">https://osmosis.org/learn/Cystic_fibrosis</a>   |
| 42: Farmacología de la motilidad gastrointestinal   | Cholinomimetics: Direct Agonists                                | <a href="https://www.osmosis.org/learn/Cholinomimetics:_Direct_agonists">https://www.osmosis.org/learn/Cholinomimetics:_Direct_agonists</a>   |



## Farmacología humana, 7.ª edición



| Capítulo del libro  | Título del video   | URL   |
|---|--|---|
| 43: Farmacología de la secreción gastrointestinal y de la ulceración mucosa digestiva | Non-biologic disease modifying anti-rheumatic drugs (DMARDs) | <a href="https://www.osmosis.org/learn/Non-biologic_disease_modifying_anti-rheumatic_drugs_(DMARDs)">https://www.osmosis.org/learn/Non-biologic_disease_modifying_anti-rheumatic_drugs_(DMARDs)</a> |
| 43: Farmacología de la secreción gastrointestinal y de la ulceración mucosa digestiva | Acid reducing medications                                    | <a href="https://osmosis.org/learn/Acid_reducing_medications">https://osmosis.org/learn/Acid_reducing_medications</a>   |
| 43: Farmacología de la secreción gastrointestinal y de la ulceración mucosa digestiva | Antidiarrheals   | <a href="https://osmosis.org/learn/Antidiarrheals">https://osmosis.org/learn/Antidiarrheals</a>   |
| 44: Farmacología de la hemostasia, la coagulación y la fibrinólisis                   | Anticoagulants: Direct factor inhibitors                     | <a href="https://osmosis.org/learn/Anticoagulants:_Direct_factor_inhibitors">https://osmosis.org/learn/Anticoagulants:_Direct_factor_inhibitors</a>   |
| 44: Farmacología de la hemostasia, la coagulación y la fibrinólisis                   | Anticoagulants: Heparin                                      | <a href="https://osmosis.org/learn/Anticoagulants:_Heparin">https://osmosis.org/learn/Anticoagulants:_Heparin</a>   |
| 44: Farmacología de la hemostasia, la coagulación y la fibrinólisis                   | Anticoagulants: Warfarin                                     | <a href="https://osmosis.org/learn/Anticoagulants:_Warfarin">https://osmosis.org/learn/Anticoagulants:_Warfarin</a>   |
| 44: Farmacología de la hemostasia, la coagulación y la fibrinólisis                   | Antiplatelet medications                                     | <a href="https://osmosis.org/learn/Anti-platelet_medications">https://osmosis.org/learn/Anti-platelet_medications</a>   |
| 44: Farmacología de la hemostasia, la coagulación y la fibrinólisis                   | Thrombolytics  | <a href="https://osmosis.org/learn/Thrombolytics">https://osmosis.org/learn/Thrombolytics</a>   |
| 45: Fármacos antianémicos y factores de crecimiento hemopoyético                      | Folate (Vitamin B9) deficiency                               | <a href="https://osmosis.org/learn/Folate_(Vitamin_B9)_deficiency">https://osmosis.org/learn/Folate_(Vitamin_B9)_deficiency</a>   |
| 45: Fármacos antianémicos y factores de crecimiento hemopoyético                      | Hematopoietic medications                                    | <a href="https://osmosis.org/learn/Hematopoietic_medications">https://osmosis.org/learn/Hematopoietic_medications</a>   |
| 45: Fármacos antianémicos y factores de crecimiento hemopoyético                      | Iron deficiency anemia                                       | <a href="https://osmosis.org/learn/Iron_deficiency_anemia">https://osmosis.org/learn/Iron_deficiency_anemia</a>   |
| 45: Fármacos antianémicos y factores de crecimiento hemopoyético                      | Vitamin B12 deficiency                                       | <a href="https://osmosis.org/learn/Vitamin_B12_deficiency">https://osmosis.org/learn/Vitamin_B12_deficiency</a>   |
| 46: Fármacos diuréticos   | Loop diuretics   | <a href="https://osmosis.org/learn/Loop_diuretics">https://osmosis.org/learn/Loop_diuretics</a>   |
| 46: Fármacos diuréticos   | Carbonic anhydrase inhibitors                                | <a href="https://osmosis.org/learn/Carbonic_anhydrase_inhibitors">https://osmosis.org/learn/Carbonic_anhydrase_inhibitors</a>   |
| 46: Fármacos diuréticos   | Osmotic diuretics  | <a href="https://osmosis.org/learn/Osmotic_diuretics">https://osmosis.org/learn/Osmotic_diuretics</a>   |
| 46: Fármacos diuréticos   | Potassium sparing diuretics                                  | <a href="https://osmosis.org/learn/Potassium_sparing_diuretics">https://osmosis.org/learn/Potassium_sparing_diuretics</a>   |
| 46: Fármacos diuréticos   | Thiazide and thiazide-like diuretics                         | <a href="https://osmosis.org/learn/Thiazide_and_thiazide-like_diuretics">https://osmosis.org/learn/Thiazide_and_thiazide-like_diuretics</a>   |



## Farmacología humana, 7.<sup>a</sup> edición




| Capítulo del libro  | Título del video                                     | URL   |
|---|--|---|
| 47: Hormonas hipotalámicas y adenohipofisarias  | Adrenocorticotropic hormone                          | <a href="https://osmosis.org/learn/Adrenocorticotropic_hormone">https://osmosis.org/learn/Adrenocorticotropic_hormone</a>   |
| 47: Hormonas hipotalámicas y adenohipofisarias  | Endocrine system anatomy and physiology              | <a href="https://osmosis.org/learn/Endocrine_anatomy_and_physiology">https://osmosis.org/learn/Endocrine_anatomy_and_physiology</a>   |
| 47: Hormonas hipotalámicas y adenohipofisarias  | Growth hormone and somatostatin                      | <a href="https://osmosis.org/learn/Growth_hormone_and_somatostatin">https://osmosis.org/learn/Growth_hormone_and_somatostatin</a>   |
| 48: Hormonas neurohipofisarias. Fármacos antidiuréticos y acuaréticos. Farmacología uterina | Antidiuretic hormone                                 | <a href="https://osmosis.org/learn/Antidiuretic_hormone">https://osmosis.org/learn/Antidiuretic_hormone</a>   |
| 48: Hormonas neurohipofisarias. Fármacos antidiuréticos y acuaréticos. Farmacología uterina | Oxytocin and prolactin                               | <a href="https://osmosis.org/learn/Oxytocin_and_prolactin">https://osmosis.org/learn/Oxytocin_and_prolactin</a>   |
| 48: Hormonas neurohipofisarias. Fármacos antidiuréticos y acuaréticos. Farmacología uterina | Uterine stimulants and relaxants                     | <a href="https://osmosis.org/learn/Uterine_stimulants_and_relaxants">https://osmosis.org/learn/Uterine_stimulants_and_relaxants</a>   |
| 49: Hormonas sexuales: estrógenos, gestágenos, andrógenos y anticonceptivos hormonales      | Androgens and antiandrogens                          | <a href="https://osmosis.org/learn/Androgens_and_antiandrogens">https://osmosis.org/learn/Androgens_and_antiandrogens</a>   |
| 49: Hormonas sexuales: estrógenos, gestágenos, andrógenos y anticonceptivos hormonales      | Aromatase Inhibitors                                 | <a href="https://www.osmosis.org/learn/Aromatase_inhibitors">https://www.osmosis.org/learn/Aromatase_inhibitors</a>   |
| 49: Hormonas sexuales: estrógenos, gestágenos, andrógenos y anticonceptivos hormonales      | Estrogens and antiestrogens                          | <a href="https://osmosis.org/learn/Estrogens_and_antiestrogens">https://osmosis.org/learn/Estrogens_and_antiestrogens</a>   |
| 49: Hormonas sexuales: estrógenos, gestágenos, andrógenos y anticonceptivos hormonales      | Progestins and antiprogestins                        | <a href="https://osmosis.org/learn/Progestins_and_antiprogestins">https://osmosis.org/learn/Progestins_and_antiprogestins</a>   |
| 50: Esteroides corticales y antiinflamatorios esteroideos                                   | Glucocorticoids                                      | <a href="https://osmosis.org/learn/Glucocorticoids">https://osmosis.org/learn/Glucocorticoids</a>   |
| 50: Esteroides corticales y antiinflamatorios esteroideos                                   | Mineralocorticoids and mineralocorticoid antagonists | <a href="https://osmosis.org/learn/Mineralocorticoids_and_mineralocorticoid_antagonists">https://osmosis.org/learn/Mineralocorticoids_and_mineralocorticoid_antagonists</a> |
| 51: Hormonas tiroideas y fármacos antitiroideos   | Hyperthyroidism medications                          | <a href="https://osmosis.org/learn/Hyperthyroidism_medications">https://osmosis.org/learn/Hyperthyroidism_medications</a>   |
| 51: Hormonas tiroideas y fármacos antitiroideos   | Hypothyroidism medications                           | <a href="https://osmosis.org/learn/Hypothyroidism_medications">https://osmosis.org/learn/Hypothyroidism_medications</a>   |
| 51: Hormonas tiroideas y fármacos antitiroideos   | Thyroid hormones                                     | <a href="https://osmosis.org/learn/Thyroid_hormone">https://osmosis.org/learn/Thyroid_hormone</a>   |
| 52: Insulina y fármacos antidiabéticos. Glucagón  | Hypoglycemics: Insulin secretagogues                 | <a href="https://osmosis.org/learn/Hypoglycemics:_insulin_secretagogues">https://osmosis.org/learn/Hypoglycemics:_insulin_secretagogues</a>                                 |
| 52: Insulina y fármacos antidiabéticos. Glucagón  | Insulins   | <a href="https://osmosis.org/learn/Insulins">https://osmosis.org/learn/Insulins</a>   |
| 52: Insulina y fármacos antidiabéticos. Glucagón  | Miscellaneous hypoglycemics                          | <a href="https://osmosis.org/learn/Miscellaneous_hypoglycemics">https://osmosis.org/learn/Miscellaneous_hypoglycemics</a>   |



## Farmacología humana, 7.ª edición




| Capítulo del libro   | Título del video   | URL   |
|--|--|---|
| 53: Fármacos hipolipoproteínicos. Control de la obesidad     | Lipid-lowering medications: Statins  | <a href="https://osmosis.org/learn/Lipid-lowering%20medications%3A%20Statins">https://osmosis.org/learn/Lipid-lowering medications: Statins</a>   |
| 53: Fármacos hipolipoproteínicos. Control de la obesidad     | Miscellaneous lipid-lowering medications   | <a href="https://osmosis.org/learn/Miscellaneous%20lipid-lowering%20medications">https://osmosis.org/learn/Miscellaneous lipid-lowering medications</a>   |
| 53: Fármacos hipolipoproteínicos. Control de la obesidad     | Calcitonin   | <a href="https://osmosis.org/learn/Calcitonin">https://osmosis.org/learn/Calcitonin</a>   |
| 54: Farmacología del calcio y el fósforo, y de su regulación | Osteoporosis medications   | <a href="https://osmosis.org/learn/Osteoporosis%20medications">https://osmosis.org/learn/Osteoporosis medications</a>   |
| 54: Farmacología del calcio y el fósforo, y de su regulación | Parathyroid hormone  | <a href="https://osmosis.org/learn/Parathyroid%20hormone">https://osmosis.org/learn/Parathyroid hormone</a>   |
| 54: Farmacología del calcio y el fósforo, y de su regulación | Phosphate, calcium and magnesium homeostasis   | <a href="https://osmosis.org/learn/Phosphate,%20calcium,%20and%20magnesium%20homeostasis">https://osmosis.org/learn/Phosphate, calcium, and magnesium homeostasis</a>   |
| 54: Farmacología del calcio y el fósforo, y de su regulación | Vitamin D  | <a href="https://osmosis.org/learn/Vitamin%20D">https://osmosis.org/learn/Vitamin D</a>   |
| 54: Farmacología del calcio y el fósforo, y de su regulación | Antigout medications   | <a href="https://osmosis.org/learn/Antigout%20medications">https://osmosis.org/learn/Antigout medications</a>   |
| 55: Fármacos hipouricémicos y antigotosos                    | Fat soluble vitamin deficiency and toxicity: Pathology review                          | <a href="https://www.osmosis.org/learn/Fat-soluble%20vitamin%20deficiency%20and%20toxicity%3A%20Pathology%20review">https://www.osmosis.org/learn/Fat-soluble vitamin deficiency and toxicity: Pathology Review</a>   |
| 56: Vitaminas liposolubles e hidrosolubles                   | Water-soluble vitamin deficiency and toxicity: B1-B7: Pathology review                 | <a href="https://www.osmosis.org/learn/Water-soluble%20vitamin%20deficiency%20and%20toxicity%3A%20B1-B7%3A%20Pathology%20review">https://www.osmosis.org/learn/Water-soluble vitamin deficiency and toxicity: B1-B7: Pathology review</a>   |
| 56: Vitaminas liposolubles e hidrosolubles                   | Water-soluble vitamin deficiency and toxicity: B9, B12 and vitamin C: Pathology review | <a href="https://www.osmosis.org/learn/Water-soluble%20vitamin%20deficiency%20and%20toxicity%3A%20B9,%20B12%20and%20vitamin%20C%3A%20Pathology%20review">https://www.osmosis.org/learn/Water-soluble vitamin deficiency and toxicity: B9, B12 and vitamin C: Pathology review</a> |
| 56: Vitaminas liposolubles e hidrosolubles                   | Antimetabolites for cancer treatment   | <a href="https://osmosis.org/learn/Antimetabolites%20for%20cancer%20treatment">https://osmosis.org/learn/Antimetabolites for cancer treatment</a>   |
| 57: Quimioterapia citotóxica                                 | Anti-tumor antibiotics   | <a href="https://osmosis.org/learn/Anti-tumor%20antibiotics">https://osmosis.org/learn/Anti-tumor antibiotics</a>   |
| 57: Quimioterapia citotóxica                                 | DNA alkylating medications   | <a href="https://osmosis.org/learn/DNA%20alkylating%20medications">https://osmosis.org/learn/DNA Alkylating medications</a>   |
| 57: Quimioterapia citotóxica                                 | Microtubule inhibitors   | <a href="https://osmosis.org/learn/Microtubule%20inhibitors">https://osmosis.org/learn/Microtubule inhibitors</a>   |
| 57: Quimioterapia citotóxica                                 | Platinum containing medications  | <a href="https://osmosis.org/learn/Platinum%20containing%20medications">https://osmosis.org/learn/Platinum containing medications</a>   |
| 57: Quimioterapia citotóxica                                 | Ribonucleotide reductase inhibitors  | <a href="https://osmosis.org/learn/Ribonucleotide%20reductase%20inhibitors">https://osmosis.org/learn/Ribonucleotide reductase inhibitors</a>   |



## Farmacología humana, 7.<sup>a</sup> edición



| Capítulo del libro   | Título del video                               | URL   |
|--|--|---|
| 57: Quimioterapia citotóxica   | Topoisomerase inhibitors                       | <a href="https://osmosis.org/learn/Topoisomerase_inhibitors">https://osmosis.org/learn/Topoisomerase_inhibitors</a>   |
| 57: Quimioterapia citotóxica   | Monoclonal antibodies                          | <a href="https://osmosis.org/learn/Monoclonal_antibodies">https://osmosis.org/learn/Monoclonal_antibodies</a>   |
| 58: Terapias antineoplásicas dirigidas   | Monoclonal antibodies                          | <a href="https://osmosis.org/learn/Monoclonal_antibodies">https://osmosis.org/learn/Monoclonal_antibodies</a>   |
| 59: Farmacología de las enfermedades infecciosas: principios generales, selección y asociaciones de antibióticos | Mechanisms of antibiotic resistance            | <a href="https://www.osmosis.org/learn/Mechanisms_of_antibiotic_resistance">https://www.osmosis.org/learn/Mechanisms_of_antibiotic_resistance</a>               |
| 60: Antibióticos $\beta$ -lactámicos   | Cell wall synthesis inhibitors: Cephalosporins | <a href="https://osmosis.org/learn/Cell_wall_synthesis_inhibitors:_Cephalosporins">https://osmosis.org/learn/Cell_wall_synthesis_inhibitors:_Cephalosporins</a> |
| 60: Antibióticos $\beta$ -lactámicos   | Cell wall synthesis inhibitors: Penicillins    | <a href="https://osmosis.org/learn/Cell_wall_synthesis_inhibitors:_Penicillins">https://osmosis.org/learn/Cell_wall_synthesis_inhibitors:_Penicillins</a>       |
| 60: Antibióticos $\beta$ -lactámicos   | Miscellaneous cell wall synthesis inhibitors   | <a href="https://osmosis.org/learn/Miscellaneous_cell_wall_synthesis_inhibitors">https://osmosis.org/learn/Miscellaneous_cell_wall_synthesis_inhibitors</a>     |
| 61: Antibióticos aminoglucósidos   | Protein synthesis inhibitors: Aminoglycosides  | <a href="https://osmosis.org/learn/Protein_synthesis_inhibitors:_Aminoglycosides">https://osmosis.org/learn/Protein_synthesis_inhibitors:_Aminoglycosides</a>   |
| 62: Antibióticos glucopéptidos. Oxazolidinonas. Estreptograminas   | Miscellaneous protein synthesis inhibitors     | <a href="https://osmosis.org/learn/Miscellaneous_protein_synthesis_inhibitors">https://osmosis.org/learn/Miscellaneous_protein_synthesis_inhibitors</a>         |
| 63: Macrólidos. Cetólidos. Lincosamidas. Tetraciclinas. Cloranfenicol. Otros antibióticos                        | DNA synthesis inhibitors: Metronidazole        | <a href="https://osmosis.org/learn/DNA_synthesis_inhibitors:_Metronidazole">https://osmosis.org/learn/DNA_synthesis_inhibitors:_Metronidazole</a>               |
| 63: Macrólidos. Cetólidos. Lincosamidas. Tetraciclinas. Cloranfenicol. Otros antibióticos                        | Miscellaneous protein synthesis inhibitors     | <a href="https://osmosis.org/learn/Miscellaneous_protein_synthesis_inhibitors">https://osmosis.org/learn/Miscellaneous_protein_synthesis_inhibitors</a>         |
| 63: Macrólidos. Cetólidos. Lincosamidas. Tetraciclinas. Cloranfenicol. Otros antibióticos                        | Protein synthesis inhibitors: Tetracyclines    | <a href="https://osmosis.org/learn/Protein_synthesis_inhibitors:_Tetracyclines">https://osmosis.org/learn/Protein_synthesis_inhibitors:_Tetracyclines</a>       |
| 64: Quinolonas. Sulfamidas. Trimetoprima. Cotrimoxazol. Nitrofurantoína. Antisépticos                            | Antimetabolites: Sulfonamides and trimethoprim | <a href="https://osmosis.org/learn/Antimetabolites:_Sulfonamides_and_trimethoprim">https://osmosis.org/learn/Antimetabolites:_Sulfonamides_and_trimethoprim</a> |
| 64: Quinolonas. Sulfamidas. Trimetoprima. Cotrimoxazol. Nitrofurantoína. Antisépticos                            | DNA synthesis inhibitors: Fluoroquinolones     | <a href="https://osmosis.org/learn/DNA_synthesis_inhibitors:_Fluoroquinolones">https://osmosis.org/learn/DNA_synthesis_inhibitors:_Fluoroquinolones</a>         |
| 65: Farmacología de las infecciones por micobacterias  | Antituberculosis medications                   | <a href="https://osmosis.org/learn/Antituberculosis_medications">https://osmosis.org/learn/Antituberculosis_medications</a>                                     |
| 66: Fármacos antifúngicos  | Azoles   | <a href="https://osmosis.org/learn/Antifungal:_Imidazoles">https://osmosis.org/learn/Antifungal:_Imidazoles</a>   |
| 66: Fármacos antifúngicos  | Echinocandins                                  | <a href="https://osmosis.org/learn/Antifungal:_Echinocandins">https://osmosis.org/learn/Antifungal:_Echinocandins</a>   |



## Farmacología humana, 7.<sup>a</sup> edición



| Capítulo del libro  | Título del video   | URL   |
|---|--|---|
| 66: Fármacos antifúngicos   | Miscellaneous antifungal medications                     | <a href="https://osmosis.org/learn/Miscellaneous_antifungal_medications">https://osmosis.org/learn/Miscellaneous_antifungal_medications</a>   |
| 67: Farmacología de las infecciones por virus, no VIH               | Hepatitis medications                                    | <a href="https://osmosis.org/learn/Hepatitis_medications">https://osmosis.org/learn/Hepatitis_medications</a>   |
| 67: Farmacología de las infecciones por virus, no VIH               | Herpesvirus medications                                  | <a href="https://osmosis.org/learn/Herpes_medications">https://osmosis.org/learn/Herpes_medications</a>   |
| 67: Farmacología de las infecciones por virus, no VIH               | Neuraminidase inhibitors                                 | <a href="https://osmosis.org/learn/Neuraminidase_inhibitors">https://osmosis.org/learn/Neuraminidase_inhibitors</a>   |
| 68: Farmacología de las infecciones por virus, VIH                  | Integrase and entry inhibitors                           | <a href="https://osmosis.org/learn/Integrase_and_entry_inhibitors">https://osmosis.org/learn/Integrase_and_entry_inhibitors</a>   |
| 68: Farmacología de las infecciones por virus, VIH                  | Non-nucleoside reverse transcriptase inhibitors (NNRTIs) | <a href="https://osmosis.org/learn/Non-nucleoside_reverse_transcriptase_inhibitors">https://osmosis.org/learn/Non-nucleoside_reverse_transcriptase_inhibitors</a>                       |
| 68: Farmacología de las infecciones por virus, VIH                  | Nucleoside reverse transcriptase inhibitors (NRTIs)      | <a href="https://osmosis.org/learn/Nucleoside_reverse_transcriptase_inhibitors">https://osmosis.org/learn/Nucleoside_reverse_transcriptase_inhibitors</a>                               |
| 68: Farmacología de las infecciones por virus, VIH                  | Protease inhibitors                                      | <a href="https://osmosis.org/learn/Protease_inhibitors">https://osmosis.org/learn/Protease_inhibitors</a>   |
| 69: Fármacos antiparasitarios: protozoos, helmintos y ectoparásitos | Anthelmintic medications                                 | <a href="https://osmosis.org/learn/Antihelminthic_medications">https://osmosis.org/learn/Antihelminthic_medications</a>   |
| 69: Fármacos antiparasitarios: protozoos, helmintos y ectoparásitos | Antimalarials  | <a href="https://osmosis.org/learn/Antimalarials">https://osmosis.org/learn/Antimalarials</a>   |
| 69: Fármacos antiparasitarios: protozoos, helmintos y ectoparásitos | Anti-mite and louse medications                          | <a href="https://osmosis.org/learn/Anti-mite_and_lice_medications">https://osmosis.org/learn/Anti-mite_and_lice_medications</a>   |
| 70: Metales: toxicología y antídotos                                | Environmental and chemical toxicities: Pathology review  | <a href="https://www.osmosis.org/learn/Environmental_and_chemical_toxicities_Pathology_review">https://www.osmosis.org/learn/Environmental_and_chemical_toxicities_Pathology_review</a> |